{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":2,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"CheckMate 651","nct_id":"NCT02741570","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-651-nct02741570. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"CheckMate 651","arms":[{"description":"Specified dose on specified days","label":"Nivolumab and Ipilimumab","type":"EXPERIMENTAL"},{"description":"Specified dose on specified days","label":"Extreme Regimen","type":"ACTIVE_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2022-09-22","type":"ACTUAL"},"conditions":["Head and Neck Cancer"],"enrollment":{"count":947,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","type":"BIOLOGICAL"},{"name":"Ipilimumab","type":"BIOLOGICAL"},{"name":"Cetuximab/Erbitux","type":"DRUG"},{"name":"Cisplatin/Platinol","type":"DRUG"},{"name":"Carboplatin/Paraplatin","type":"DRUG"},{"name":"Fluorouracil/Adrucil","type":"DRUG"}],"last_update":"2023-09-21","lead_sponsor":"Bristol-Myers Squibb","official_title":"An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-05-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20","timeFrame":"From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)"},{"measure":"Overall Survival (OS) in All Randomized Participants","timeFrame":"From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)"}],"references":[{"citation":"Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Muller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6.","pmid":"36473143","type":"DERIVED"},{"citation":"Hwang M, Seiwert TY. Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. Lancet Oncol. 2021 Apr;22(4):413-415. doi: 10.1016/S1470-2045(21)00121-2. Epub 2021 Mar 5. No abstract available.","pmid":"33684371","type":"DERIVED"}],"start_date":{"date":"2016-10-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT02741570"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-651-nct02741570"}